Condition: Acute Lymphoblastic Leukemia · Sponsor: Nanfang Hospital, Southern Medical University
This prospective, randomized, controlled trial evaluates the efficacy and safety of a new targeted drug combined with chemotherapy versus standard chemotherapy alone. Eligible patients were randomized 1:1 to either the treatment or control group.
This description comes directly from the study's public registry record.
Olivia Jiang · 02061641611 · 18956985366@163.com
Always discuss trial participation with your own doctor first.
| Department of Hematology,Nanfang Hospital, Southern Medical University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07203352